Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-026322
Filing Date
2022-07-19
Accepted
2022-07-19 16:15:26
Documents
2
Period of Report
2022-07-15

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 4115
2 EX-24.1 DOCUMENT attachment1.htm EX-24.1 4580
  Complete submission text file 0000899243-22-026322.txt   10049
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Issuer) CIK: 0001680581 (see all company filings)

EIN.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address
Tourangeau Greg (Reporting) CIK: 0001916566 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38978 | Film No.: 221091720